Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells

被引:97
作者
Hölig, P
Bach, M
Völkel, T
Nahde, T
Hoffmann, S
Müller, R
Kontermann, RE
机构
[1] Vectron Therapeut AG, D-35037 Marburg, Germany
[2] Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35033 Marburg, Germany
关键词
drug delivery; integrins; phage display; RGD peptides; vascular targeting;
D O I
10.1093/protein/gzh055
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
RGD peptides targeting alpha(v)-integrins are promising ligands for the generation of vascular targeting agents. We isolated from phage display RGD motif libraries novel high-affinity cyclic RGD peptides by selection on either endothelial or melanoma cells. Although the starting sequences contained only two cysteine residues flanking the RGD motif, several of the isolated peptides possessed four cysteine residues. A high-affinity peptide (RGD10) constrained by only one disulfide bond was used to generate novel lipopeptides composed of a lipid anchor, a short flexible spacer and the peptide ligand conjugated to the spacer end. Incorporation of RGD10 lipopeptides into liposomes resulted in specific and efficient binding of the liposomes to integrin-expressing cells. In vivo experiments applying doxorubicin-loaded RGD10 liposomes in a C26 colon carcinoma mouse model demonstrated improved efficacy compared with free doxorubicin and untargeted liposomes.
引用
收藏
页码:433 / 441
页数:9
相关论文
共 37 条
  • [21] INTEGRIN EXPRESSION IN MALIGNANT-MELANOMA
    KRAMER, RH
    VU, M
    CHENG, YF
    RAMOS, DM
    [J]. CANCER AND METASTASIS REVIEWS, 1991, 10 (01) : 49 - 59
  • [22] Use of phage display to probe the evolution of binding specificity and affinity in integrins
    Li, RH
    Hoess, RH
    Bennett, JS
    DeGrado, WF
    [J]. PROTEIN ENGINEERING, 2003, 16 (01): : 65 - 72
  • [23] Immunoliposomes for the targeted delivery of antitumor drugs
    Mastrobattista, E
    Koning, GA
    Storm, G
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1999, 40 (1-2) : 103 - 127
  • [24] Tumor angiogenesis as a therapeutic target
    Matter, A
    [J]. DRUG DISCOVERY TODAY, 2001, 6 (19) : 1005 - 1024
  • [25] Highly efficient transduction of endothelial cells by targeted artificial virus-like particles
    Müller, K
    Nahde, T
    Fahr, A
    Müller, R
    Brüsselbach, S
    [J]. CANCER GENE THERAPY, 2001, 8 (02) : 107 - 117
  • [26] Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display
    Nicklin, SA
    White, SJ
    Watkins, SJ
    Hawkins, RE
    Baker, AH
    [J]. CIRCULATION, 2000, 102 (02) : 231 - 237
  • [27] alpha v Integrins as receptors for tumor targeting by circulating ligands
    Pasqualini, R
    Koivunen, E
    Ruoslahti, E
    [J]. NATURE BIOTECHNOLOGY, 1997, 15 (06) : 542 - 546
  • [28] Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human αvβ3 integrin
    Richards, J
    Miller, M
    Abend, J
    Koide, A
    Koide, S
    Dewhurst, S
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2003, 326 (05) : 1475 - 1488
  • [29] Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin
    Schiffelers, RM
    Koning, GA
    ten Hagen, TLM
    Fens, MHAM
    Schraa, AJ
    Janssen, ANPCA
    Kok, RJ
    Molema, G
    Storm, G
    [J]. JOURNAL OF CONTROLLED RELEASE, 2003, 91 (1-2) : 115 - 122
  • [30] Targeting of RGD-modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study
    Schraa, AJ
    Kok, RJ
    Moorlag, HE
    Bos, EJ
    Proost, JH
    Meijer, DKF
    de Leu, LFMH
    Molema, G
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (05) : 469 - 475